ClinicalTrials.gg
Not yet recruitingNCT06180499ILDTreg2Updated Feb 14, 2024

Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion

A Phase 1/2 interventional study of T-reg depleted DLI in Hematological Malignancies, Regulatory T Cell Depletion and Relapse, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-14.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 6 under way, 1 of them phase 3. Hematologic Neoplasms · Assistance Publique - Hôpitaux de Paris.

Started
2024
with 1 other
Phase 1/2
4 of 16
2 open now
Registered
15th of 16
by date

Among the 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris, this one is one of 2 that started in 2024, is one of 4 in phase 1/2, and was the 15th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

6 of the 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hematologic Neoplasms by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Since the discovery that Treg suppress anti-tumor immune responses, inhibiting their function has become a major challenge for the development of efficient immunotherapy for cancer. In humans, we previously reported the positive results of a first clinical trial using Treg depletion for anti-tumor response amplification in the field of allogeneic hematopoietic stem cell transplantation (HSCT). The present project aims at developing this anti-tumor immunotherapeutic strategy in the same setting, i.e. donor lymphocyte infusion (DLI) for relapsing hematological malignancies after HSCT, using a new selection marker: CD127. The choice of this new strategy is supported by our results of a retrospective clinical study and pre-clinical data. Using human cells, this studies demonstrated, in vitro and in vivo in animal murine models, that Treg depletion through CD127 positive selection is much more efficient to improve allogeneic immune responses of donor T-cells as compared to the previous strategy using the CD25 marker.

03

Conditions studied

  • Hematological Malignancies
  • Regulatory T Cell Depletion
  • Relapse

Keywords

  • DLI
  • Regulatory T cells depletion
  • Hematological malignancies
  • Relapse
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (older than 18 years old without upper limit of age) diagnosed with leukemia, myelodysplasia, myeloproliferative disorder or lymphoproliferative disorder (CLL, myeloma, lymphoma)
  • Previous HSCT from a matched sibling, haplo-identical or unrelated donor (any type of conditioning regimen)
  • Haematological relapse (molecular, cytogenetic or cytological) after HSCT
  • Patient (no or partial response) to one or several previous standard unmanipulated DLI
  • Availability of cryopreserved lymphapheresis
  • No loss of chance by using of DLI rather than more incisive anti-tumor agents according to investigator appreciation
  • Written before any intervention necessary for the trial
  • Affiliation to a social security regime
  • Negative pregnancy test for women of childbearing age participating in the study
  • Effective methods for men / women in line with the current CTFG recommendations version 1.1

Exclusion criteria

Exclusion Criteria:

  • Acute grade ≥ II or moderate/severe chronic at the time of inclusion
  • Patient receiving treatment for GVHD or any other reason
  • \< 50 ml/min
  • Serum (AST)/serum glutamic-oxaloacetic transaminase (SGOT) or alanine transaminase (ALT)/serum glutamate pyruvate transaminase (SGPT) > 5.0 x (ULN)
  • Serum total > 50µM (expect for unconjugated hyperbilirubinemia due to Gilbert's disease)
  • Performance status >1
  • Severe infection according to grading (grade>2)
  • Pregnant or lactating women
  • Patient under tutorship, curatorship or legal protection
  • Ongoing participation in another interventional research protocol within the same field of immune modulation (through cell therapy or not)
  • State medical aid
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    T-reg depleted DLI

    Drug: T-reg depleted DLI

Interventions

  • DrugT-reg depleted DLI

    Treg depleted Donor Lymphocytes Infusion

06

What researchers measure

Primary outcomes

  1. cumulative incidence of GVHD in its acute grade ≥ II and/or severe chronic form (according Glucksberg-Thomas and NIH scales, respectively), and uncontrolled after a 14-day immunosuppressive course including steroids.

    Composite criteria. In this evaluation, death from non-GVHD cause will be taken as a competitive event

    Time frame: occurring within the 2 months following d-DLI infusion

Secondary outcomes

  1. Incidence of acute and/or chronic GVHD, with corresponding grades according to NIH and Glucksberg-Thomas scales

    Time frame: at 2 and 12 month

  2. Date of putative relapse/progression for estimation of cumulative incidence (taking into account the competitive risk of death not related to relapse)

    Time frame: at 2 and 12 month

  3. Date of putative relapse/progression for estimation disease-free survival

    Time frame: at 2 and 12 month

  4. Number, causes and date of deaths

    Time frame: at 2 and 12 month

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2024; primary completion for Nov 2028, 56 months later.

Of 64 phase 1/2 interventional studies under Hematologic Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 127. This study's planned 56 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2023
First posted
Dec 22, 2023
StartEst.
Mar 2024
Primary completionEst.
Nov 2028
CompletionEst.
Sep 2029
Last update
Feb 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06180499
Responsible party
Sponsor
First posted
Dec 22, 2023
Start date
Mar 2024 (estimated)
Primary completion
Nov 2028 (estimated)
Completion
Sep 2029 (estimated)
Last update
Feb 14, 2024

Study contacts

sébastien maury, PhD
Contact
sebastien.maury@aphp.fr
01.49.81.20.57 ext. +33
elodie lemadre, M.Sc
Contact
elodie.lemadre@aphp.fr
01 44 84 17 34 ext. +33
elodie lemadre, M.Sc
study chair · APHP

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion